The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis

Alessandro Isidori, Francesco Merli, Francesco Angrilli, Felicetto Ferrara, Francesco Alesiani, Giuseppe Visani

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)148-149
Number of pages2
JournalLeukemia and Lymphoma
Volume52
Issue number1
DOIs
Publication statusPublished - Jan 2011

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this